Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation
Authors
Keywords
-
Journal
BLOOD
Volume 120, Issue 14, Pages 2899-2908
Publisher
American Society of Hematology
Online
2012-07-05
DOI
10.1182/blood-2011-07-368720
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell–Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303
- (2011) Steven M. Devine et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Inhibition of IL-32 activation by -1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model
- (2011) A. M. Marcondes et al. BLOOD
- PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
- (2011) K Dredge et al. BRITISH JOURNAL OF CANCER
- Danger signals activating innate immunity in graft-versus-host disease
- (2011) Robert Zeiser et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation
- (2011) I. Tawara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses
- (2010) Xiaopei Huang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Prevention of GVHD without losing GVL effect: windows of opportunity
- (2010) Ping Zhang et al. IMMUNOLOGIC RESEARCH
- Graft-versus-Host Disease Is Independent of Innate Signaling Pathways Triggered by Pathogens in Host Hematopoietic Cells
- (2010) H. Li et al. JOURNAL OF IMMUNOLOGY
- Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis
- (2010) Menachem Bitan et al. MOLECULAR IMMUNOLOGY
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell Transplantation
- (2010) Menachem Bitan et al. PLoS One
- Regulation of Adaptive Immunity by the Innate Immune System
- (2010) A. Iwasaki et al. SCIENCE
- Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies
- (2010) Steven C Goldstein et al. Expert Review of Hematology
- Hyaluronan Mediates Ozone-induced Airway Hyperresponsiveness in Mice
- (2009) Stavros Garantziotis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Graft-versus-host disease
- (2009) James LM Ferrara et al. LANCET
- Alpha1-Antitrypsin Deficiency
- (2009) Edwin K. Silverman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection
- (2008) M. Quigley et al. BLOOD
- TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection
- (2008) P. A. Taylor et al. BLOOD
- Heparanase prevents the development of type 1 diabetes in non‐obese diabetic mice by regulating T‐cell activation and cytokines production
- (2008) Menachem Bitan et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Curative and cell regenerative effects of 1-antitrypsin treatment in autoimmune diabetic NOD mice
- (2008) M. Koulmanda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice
- (2008) E. C. Lewis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started